Instylla
Instylla, Inc. is a privately held medical device company headquartered in Bedford, Massachusetts, founded in 2017 by Incept LLC to develop next-generation resorbable liquid embolic agents for interventional radiology, with initial clinical applications in interventional oncology and peripheral hemostasis. Its flagship product, the Embrace Hydrogel Embolic System, received U.S. FDA premarket approval (PMA) in August 2025 for the embolization of hypervascular tumors in peripheral arteries of 5 mm or less, and began commercial use in January 2026; the company also markets the FDA-cleared Tembo Embolic System. Embrace is delivered as two injectable polyethylene-glycol precursors that crosslink in the vessel lumen into a soft hydrogel and then resorb by hydrolysis over roughly eleven months. Instylla is a device manufacturer rather than a software vendor: it publishes no developer program, no public API, and no machine-readable interface contract.
Instylla is profiled on the APIs.io network. Tagged areas include Company, Medical Devices, Healthcare, Interventional Radiology, and Oncology.
Instylla’s developer surface includes engineering blog and 10 more developer resources.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Company 7
The organization behind the API
Scroll for all 7
Other 2
Properties that don't map to a standard resource type
Source (apis.yml)
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.